Loading
Life sciences · Journal article
Journal of the American Veterinary Medical Association · September 8, 2026
A consensus or society position rather than new primary data.
This is a narrative review of immune checkpoint inhibitors (ICIs), particularly gilvetmab (anti-PD-1), in veterinary cancer care. The source documents conditional US licensure of gilvetmab for canine melanoma and mast cell tumors, with reported target engagement, acceptable tolerability, and clinical efficacy in subsets of treated dogs, but identifies substantive gaps in patient selection, biomarker development, and combination strategies that require further investigation.
Journal article. Dogs with spontaneously occurring cancers, particularly melanoma and mast cell tumors.
Gilvetmab is currently the only veterinary ICI available commercially with conditional US licensure for canine melanoma and mast cell tumors Several caninized anti-PD-1 and anti-PD-L1 antibodies have demonstrated favorable safety profiles and notable antitumor activity in spontaneously occurring canine cancers Gilvetmab has demonstrated target engagement, acceptable tolerability, and clinical efficacy in a subset of treated dogs
No specific adverse event rates or frequencies provided Several caninized anti-PD-1 and anti-PD-L1 antibodies have demonstrated favorable safety profiles and notable antitumor activity in spontaneously occurring canine cancers
Veterinary oncologists should recognize gilvetmab as a conditionally licensed option for canine melanoma and mast cell tumors, but must acknowledge limited evidence for clinical efficacy in specific subsets, the need for careful response assessment to distinguish pseudoprogression from true progression, and ongoing uncertainty about optimal patient selection and biomarker-driven strategies.
A narrative review synthesizing evidence on immune checkpoint inhibitors in veterinary oncology, identifying clinical applications, safety considerations, and research gaps rather than reporting original trial data.
Veterinary oncologists should recognize gilvetmab as a conditionally licensed option for canine melanoma and mast cell tumors, but must acknowledge limited evidence for clinical efficacy in specific subsets, the need for careful response assessment to distinguish pseudoprogression from true progression, and ongoing uncertainty about optimal patient selection and biomarker-driven strategies.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Abstract Immune checkpoint inhibitors (ICIs) have revolutionized human oncology and are emerging as a promising strategy in veterinary cancer care. These agents unleash antitumor immunity by targeting inhibitory pathways that suppress T-cell function, enabling durable responses in select patients. In dogs, the immune checkpoint programmed cell death protein 1 (PD-1) axis is a primary focus due to conserved structural and functional homology with the PD-1 axis in humans, documented PD-1/programmed death-ligand 1 (PD-L1) signaling in the canine tumor microenvironment, and its role in reversing tumor-induced immune exhaustion. Several caninized anti-PD-1 and anti-PD-L1 antibodies have demonstrated favorable safety profiles and notable antitumor activity in spontaneously occurring canine cancers, particularly melanoma and mast cell tumors. Gilvetmab, currently the only veterinary ICI available commercially, has conditional licensure in the United States for these indications. This caninized anti-PD-1 monoclonal antibody has demonstrated target engagement, acceptable tolerability, and clinical efficacy in a subset of treated dogs. Although reported adverse events are generally manageable, further work is needed to better characterize immune-mediated toxicities. Furthermore, response patterns may differ from those of cytotoxic therapies, including potential pseudoprogression, necessitating careful selection of response assessment methods. Key challenges remain in optimizing patient selection, refining biomarker development, establishing effective combination strategies, and defining the efficacy of immune checkpoint blockade across diverse tumor histologic subtypes (histotypes). Continued study of gilvetmab and related agents should advance the clinical application of immunotherapy in veterinary oncology and inform the next generation of comparative cancer care.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.